Adam M. Burgoyne

机构：University of San Diego, University of California San Diego, University of California San Diego Medical Center · ORCID：0000-0002-4351-9940

发表论文 115 篇 · 总被引 6056 次 · h-index 27

代表论文

• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study (2023 · The Lancet · 被引 704)
• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet · 被引 270)
• NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023 (2023 · Journal of the National Comprehensive Cancer Network · 被引 211)
• A second update on mapping the human genetic architecture of COVID-19 (2023 · Nature · 被引 121)
• Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study (2025 · The Lancet Oncology · 被引 67)
• Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology (2025 · Journal of the National Comprehensive Cancer Network · 被引 47)